Trials / Terminated
TerminatedNCT00309023
Study of BMS-663513 in Patients With Advanced Cancer
A Phase I/II, Ascending Multi-Dose Study of BMS-663513, An Agonistic Anti-CD137 Monoclonal Antibody, Administered Every Three Weeks to Patients With Metastatic or Locally Advanced Solid Malignancies
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 115 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I/II, ascending, multi-dose study of BMS-663513, an agonistic anti-CD137 monoclonal antibody, administered every three weeks to patients with metastatic or locally advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-663513 | mg/kg, intravenous (IV), 0.3, 1, 3, 6, 10 or 15 mg/kg, once every 3 weeks (q 3 wks), 12 weeks depending on response |
Timeline
- Start date
- 2005-12-01
- Primary completion
- 2008-12-01
- Completion
- 2009-09-01
- First posted
- 2006-03-31
- Last updated
- 2015-10-12
Locations
12 sites across 3 countries: United States, Canada, France
Source: ClinicalTrials.gov record NCT00309023. Inclusion in this directory is not an endorsement.